Table 3.
Liver transplantation for hepatoblastoma
| Database | Author | Year | Year of LT | n | Age of patients at LT | % female | Median FU |
Overall survival in % |
LDLT | ||
| 1 yr | 3 yr | 5 yr | |||||||||
| SIOPEL-3HR | Zsiros | 2010 | 1998-2004 | 31 | < 16 yr (median 21 mo) | NR | 54 mo | NR | 75% | NR | NR |
| Chicago/Toronto | Browne | 2008 | 1990-2004 | 14 | 18 mo-13 yr (mean 57 mo) | 36 | 46 mo | 71% @ 46 mo | NR | ||
| London | Faraj | 2008 | 1993-2007 | 25 | 0.5-10 yr (median 2.5 yr) | 32 | 6.8 yr | 91 | 78 | 28% | |
| Stanford | Beaunoyer | 2007 | 1988-2006 | 15 | 0.3-9.7 yr (mean 2.6 yr) | 47 | 3.3 ± 3.5 yr | 87 | 87 | 87 | 0 |
| Spain | Avila | 2006 | 11 | 6 mo-14 yr | 91 | 91 | 82 | 25% | |||
| UNOS review | Austin | 2006 | 1987-2004 | 135 | 2.9 ± 2.5 yr | 38 | 79 | 69 | |||
| Texas | Mejia | 2005 | 1995-2003 | 10 | mean 5.8 yr | 50 | Mean 10.8 yr | 70% @ last FU (mean 10.8 yr) | 20% | ||
| Kyoto | Kasahara | 2005 | 1990-2004 | 14 | NR | NR | NR | 78.6 | NR | 65.5 | 100% |
| SIOPEL-1 | Otte | 2004 | 1990-1994 | 12 | 1.25-11.6 yr (median 3.8 yr) | 42 | 117 mo | NR | NR | 75 | NR |
| Dallas | Molmenti | 2002 | 1984-2000 | 9 | 6 mo-16 yr (mean 6.4 yr) | 44 | NR | NR | 67% | NR | 0% |
| France | Chardot | 2002 | 1998-1999 | 4 | 10-60 mo (mean 17 mo) | NR | NR | 75% at last FU (13-24 mo) | 100% | ||
| Birmingham | Pimpalwar | 2002 | 1991-2000 | 12 | 0.15-8.78 yr at diag. (median 1.32 yr) | NR | NR | NR | 93% | 83% | 0 |
| Pittsburgh | Reyes | 2000 | 1989-1998 | 12 | NR | NR | NR | 92 | 92 | 83 | 0 |
LT: Liver transplantation; FU: Follow-up; LDLT: Living-donor liver transplantation; NR: Not reported; UNOS: United Network for Organ Sharing.